Post on 04-Jun-2018
8/13/2019 LMI Cofator de Ristocetina BioFlash Jornal
1/2
Vol.30 No.4 6-7/2013ISSN 1068-1760
Prostate Cancer TestCloser to Clinical Trial
AAbreakthrough urine biomarker forprostate cancer will soon be avail-
able which will signal a significant stepforward in the battle against prostatecancer. A protein called Engrailed-2(EN2) is made by prostate cancers andsecreted into urine where it can easilybe detected in a small urine sample
Contd on page 4
Novel Biomarker DetectsDeadly Lymphoma
AAnovel diagnostic test accuratelyidentifies patients who have a
new type of deadly intestinal lym-phoma that is particularly common inAsia. The test will have an immediateimpact on patient care, with doctorsnow able to diagnose patients accurate-ly and tailor more effective treatment
Contd on page 8
W O R L D S C L I N I C A L L A B O R A T O R Y N E W S L E A D E R
R E A D E R S E R V I C E P O R T A L
LINKXPRESS COM
V I S I T
If your subscriptionis not renewed every 12 monthsyour Free Subscription may be
automatically discontinued
Identify LinkXpress codes ofinterest as you read magazine
Click on LinkXpress.comto reach reader service portal
Mark code(s) of interest onLinkXpress inquiry matrix
Renew/Start yourFree Subscription
Access InteractiveDigital Magazine
Instant OnlineProduct Information:
1
2
3
PPhysicians will have access to anew noninvasive prenatal test,
which uses cell-free fetal DNA incirculating maternal blood.
The test, called Panorama, usescell-free fetal DNA in circulatingmaternal blood to screen for chro-mosomal abnormalities associatedwith trisomy 21 (Down syndrome),
trisomy 18 (Edwards syndrome), tri-somy 13 (Patau syndrome) andmonosomy X (Turner syndrome).Panorama can be used as early asthe ninth week of pregnancy.
In December 2012, the AmericanCongress of Obstetricians and Gyne-cologists (ACOG) issued a medicalopinion stating that cell-free fetal
Noninvasive Prenatal Test ScreensBlood for Chromosomal Abnormalities
DAILY CLINICAL LAB NEWS
V I S I T
Rapid Molecular Testfor Chikungunya Virus
AAnovel molecular diagnosplatform with high sensitiv
and specificity has been developfor the early detection of the Ckungunya virus(CHIKV).
Chikungunya has reemerged an important arboviral infectionglobal health significance abecause of lack of a vaccine a
Process Offers Potentia
for New BiomarkersAA
cutting-edge technology hbeen developed that can s
cessfully screen human blood disease markers that may hold tkey to better diagnosing and undstanding of puzzling health contions, including autoimmune deases. The technology accuratidentified human blood markers
Contd on pag
Contd on pag
Blood Test TracksResponse to CancerTreatment
Blood Test TracksResponse to CancerTreatment
Image: A cluster of breast cancercells showing visual evidence of
programmed cell death
Image: A cluster of breast cancercells showing visual evidence of
programmed cell deathSee article on page 13
A blood test that tracksfragments of DNA shedby dying tumor cells couldbe used to monitor how wellpatients are responding tocancer treatment, as well asprovide a non-invasive al-ternative to biopsies in ad-
vanced breast cancer.
Contd on page 6 Contd on page 33
Diagnostic Blood Test forFibromyalgia Developed
CCytokine-producing activity ofimmune cells of fibromyalgia
(FM) patients has led to the develop-ment of a commercial blood test.
The very real biological conditionof FM takes an average of three tofive years for someone with the ill-ness to get an accurate diagnosis ashitherto there was no diagnostic
INSIDE
PUBLISHED IN COOPERATION
International Federationof Clinical Chemistry
and Laboratory Medicine
Clinical News . . . . . . .IFCC News . . . . . . . . .
EFLM Corner . . . . . . . .
Product News . . . . . 2
Technical Literature 58
Industry News . . . . . . .
International Calendar
GLOBETECH
MEDIA> > >
8/13/2019 LMI Cofator de Ristocetina BioFlash Jornal
2/2LabMedica International
June-July/2013
LabMedicaLabMedica
LabMedica lnternationalis published eight times and is circuIated worldwide (outside the USACanada) without charge and by written requeclinical laboratory specialists and administratorsother qualified professionals allied to the field.
To all others: Paid Subscription is available for ayear subscription charge of US$240. Single copyis US$20. Mail your paid subscription order acco
nied with payment to Globetech Media, P.O.B. 80Miami, FL 33280-2214.
For change of address or questions on yourscription, write to:LabMedicalnternational, Circulation Ser-vices at above address; orvisit: www.LinkXpress.com
Vol.30 No.4. Published, under license, by Globetech LLC; Copyright 2013. All rights reserved. Reproducany form is forbidden without express permission. Opexpressed are solely those of the authors, and do nresent an endorsement, or lack thereof, by the Publisany products or services.
ADVERTISING SALES OFFICES
HOW TO CONTACT US
ISSN 1068-1760
SUBSCRIPTION INFORMATION
labmedica.com
EDITORIAL BOARD
Rosa I. Sierra-Amor Mexico
Claus Christiansen Denmark
Bernard Gouget France
Jocelyn M. Hicks United States
Anders Kallner Sweden
Christopher Price United Kingdom
Andreas Rothstein Colombia
Dmitry B. Saprygin Russia
Grard Siest France
Andrew Wootton United Kingdom
A GLOBETECH PUBLICAT
Published in cooperation with the International Fedeof Clinical Chemistry and Laboratory Medicine (IFCCEuropean Federation of Clinical Chemistry and LaboMedicine (EFLM).
HospiMedica International HospiMedica en Espaol HospiMedLabMedica International LabMedica en Espaol LabMediMedical Imaging International Bio Research International MedimHospiMedica.com LabMedica.com BiotechDaily.com Trade
USA P.O.Box 800806, Miam i, FL 33280, U
Doris.Mendieta@globetech.net Tel: (1) 954-893-0
GERMANY, SWITZ., AUSTRIA Bad Neustadt, Germ
Jut ta .C io lek@globetech.net Te l: (49) 9771-3
UK, FRANCE, NORDIC REG. Gerrards Cross
Paul.Mi lls@globetech.net Tel: (44) 1753-892
ITALY Genoa,
Fabio.Potesta@globetech.net Tel: (39) 10-570-4
JAPAN Tokyo, Ja
Katsuhiro.Ishii@globetech.net Tel: (81) 3-5691-3
CHINA Shenzen, Guangdong, C
Parker.Xu@globetech.net Tel: (86) 755-8375-3
ALL OTHER COUNTRIES Contact USA O
ads@globetech.net Tel: (1) 954-893-0
Teknopress Yaynclk ve Ticaret Ltd. St i. adnaImtiyaz Sahibi: M. Geren Yaz isleri Mdr: Ersin Kk
Msi r Dervis Ibrahim So k. 5/4, Esent epe, 34394 Si sl i, Istanbul, TFaks: (212) 216-6997 P. K. 1, AVPIM, 34001 Istanbul
Bask: Promat Web Ofset Tesisi Sanayi Mahallesi 1673. SoNo: 34 34510 Esenyurt, B. ekmece Istanbul, Trkiye
Yerel sreli yayndr. Ylda sekiz kere yaynlanr, cretsiz dag
Dan Gueron
Jill Roberge
Jacqueline Miller, PhD
Raymond L Jacobson, PhD
Gerald Slutzky, PhD
Andreas Rothstein
Marcela Jensen
Joseph Ciprut
Brenda Silva
Paul MillsDoris Mendieta
Dr. Jutta Ciolek
Christina Chang
Arda Turac
Elif Erkan
Subscriptions:Send Press Releases to:
Advertising & Ad Material:Other Contacts:
PublisherEditorial DirectorNews DirectorNews EditorNews EditorNews EditorAssistant EditorAssistant EditorNew Products Edito
Regional DirectorRegional DirectorRegional DirectorRegional DirectorProduction DirectorReader Service Ma
www.LinkXpress.coLMNews@globetechads@globetech.netinfo@globetech.net
AAfully automated von Willebrand Factor assay hasbeen released in Europe and international territories
as a European CE in vitro diagnostic (IVD) Mark productunder the European Directive on in vitro DiagnosticMedical Devices but not currently [US FDA] 510(k)cleared. A product of Instrumentation Laboratories(Bedford, MA, USA; www.instrumentationlaboratory.com/ilww), the fully automated HemosIL AcuStar VWFassay panel, designed exclusively for use on the ACLAcuStar Hemostasis Testing System, includes HemosILAcuStar VWF Antigen (VWF:Ag) and HemosIL AcuStarVWF Ristocetin Cofactor (VWF:RCo) Activity assays.
HemosIL AcuStar VWF:RCo is the first fully automat-
ed, chemiluminescent assay to use recombinant technol-ogy, allowing full automation and greater precision thanplatelet-based tests. It meets guidelines on VDF investiga-tion and enhances accuracy versus manual methods.Chemiluminescence offers an enhanced linearity range toquantify extremely low levels of VWF concentrations.
Like all reagents on the ACL AcuStar System,HemosIL AcuStar VWF assays are ready-to-use, car-tridge-based and offer results in 30 minutes on-demand, 24/7. This is the third specialty assay panel
commercialized on the ACL AcuStar system. Previouslyintroduced panels include Antiphospholipid Syndromeand Heparin-Induced Thrombocytopenia.
With the ACL AcuStar Hemostasis Testing System,our goal is to automate complex assays and offerenhanced efficiency and sensitivity where it mattersmost, said Remo Tazzi, Director of HemostasisMarketing at IL. Our new HemosIL AcuStar VWFassays achieve this, allowing clinicians to make quickerand more effective patient care decisions.
VDF is an acquired or inherited bleeding disorder,caused by a qualitative or quantitative defect of theVWF protein. Whereas hemophilia mainly affects
males, VDF is not gender-specific. The disease affectsover 1% of the worldwide population and occurs in1/100100,000 people with hemophilia. AcquiredVDF can be associated with serious autoimmune prob-lems (e.g., rheumatoid arthritis, systemic lupus erythe-matosus, and specific types of kidney failure or cancers)and may develop with no underlying conditions.Certain kinds of VDF may remain undiagnosed becausesymptoms can be mild. Prompt diagnosis and classifica-tion are necessary for optimal therapeutic management.
Fully-Automated von Willebrand Factor Assay Panel Released
contd from cover
from men, allowing faster testing that could save lives
and offer the potential for huge cost savings. TheUniversity of Surrey (Guildford, UK; www.surrey.ac.uk)where the test was originally developed has signed aworldwide nonexclusive agreement with internationaldiagnostic specialist Zeus Scientific (Raritan, NJ, USA;www.zeusscientific.com) to develop and market itsbreakthrough urine biomarker, EN2. Urinary EN2 lev-els can be measured by an enzyme-linked immunosor-bent assay and higher EN2 levels correlated with thestage of the tumor.
In a joint statement, the University and the ProstateProject Charity (Godalming, UK; www.prostate-project.org.uk) who jointly funded the research, said: This isthe news we have all been waiting for. In two years ofextensive trials in the USA and Europe, EN2 has consis-
tently outperformed the 30-year-old prostate-specificantigen (PSA) test proving itself to be twice as effective
at finding prostate cancer. Its accuracy has never been indoubt, but it has proved difficult to bulk test urine sam-ples using conventional assay technology. Now, ZeusScientific, one of the leaders in this field is confident itcan overcome the problems and bring EN2 to market.
Hardev Pandha MD, PhD, professor of MedicalOncology at the University of Surrey, said, TheUniversity of Surrey is looking forward very much toworking with Zeus to introduce EN2 as a novel diag-nostic test for prostate and bladder cancers. Our testshave shown that levels of EN2 correlate strongly withdisease volume. Knowledge of disease volume mayhelp urologists assess whether the patient has a smallvolume of disease that may be safely and actively mon-itored or a larger volume that needs to be treated.
Prostate Cancer Test Closer to Clinical Trial
contd from cover
neuromyelitis optica (NMO), a rare autoimmune dis-order resembling multiple sclerosis that can result inblindness and paralysis, by substituting antibody-binding targets with biologically unnatural moleculescalled peptoids.
Scientists at Scripps Research Institute (Jupiter,FL, USA; www.scripps.edu) identified several pep-toids that bound exclusively to antibodies in NMO
patient blood serum and not healthy patients orpatients with similar diseases, including multiplesclerosis (MS), lupus, Alzheimers disease (AD) andnarcolepsy. At least one of the peptoids bound to anantibody that is well known to be associated withNMO.
The team used the chemical library screeningtechnology to identify a synthetic peptoid thatbinds anti-Aquaporin 4 (AQP4) antibodies in theserum of NMO patients. After processing theserum, slides were scanned on a GenePix 4200ALmicroarray scanner (Molecular Devices;
Sunnyvale, CA, USA; www.moleculardevices.com)by using the 488/635 nm laser at 100% power anda 500-photomultiplier-tube gain.
The investigators screened 100,000 peptoids usinga second-generation bead-based screening approachthat yielded several peptoid ligands for the antigen-binding site of anti-AQP4 antibodies. They showed ina small preliminary study that the use of a small panelof these peptoids allows one to distinguish between
NMO patient serum and serum from healthy controlsor patients with MS, AD, narcolepsy, and lupus withhigh accuracy.
Thomas Kodadek, PhD, the senior author of thestudy, said, We find disease biomarkers differentlythan anyone else. This enables new disease biomark-er detection. Additionally, by using these peptoid hitsto fish for disease-specific antibodies, the systemenables disease-specific antibody detection withoutfirst knowing the antibodies natural binding targets.The study was published on March 21, 2013, in thejournal Chemistry & Biology.
Process Offers Potential for New Biomarkers